Tango registers Phase 1/2 trial pairing vopimetostat with Erasca's ERAS-0015
Tango Therapeutics listed a new study testing vopimetostat alongside Erasca's ERAS-0015 in MTAP-null pancreatic and lung cancers with RAS mutations.
Tango Therapeutics posted one new trial registration this week, with Erasca listed as a collaborator.
- TNG462-C103 is a Phase 1/2 study to investigate the safety and antitumor activity of vopimetostat (TNG462) combined with ERAS-0015 in patients with MTAP-null pancreatic or MTAP-null non-small cell lung cancer with RAS mutation.1 The study is sponsored by Tango Therapeutics with Erasca, Inc. as a collaborator. It is not yet recruiting, with an estimated start of November 2026 and an estimated enrollment of 188 participants.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.